ICONIC-ASCEND reports icotrokinra noninferiority to ustekinumab in plaque psoriasis
Company / institutional announcement · Johnson & Johnson
Source published: · Event / reporting date: 2026-11-06
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Why it may matter
Potential business implication: an active-comparator study strengthens differentiation of an oral peptide; noninferiority should not be interpreted as demonstrated superiority.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections